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Aims: To assess efﬁcacy and safety of lixisenatide once-daily versus placebo in Type 2 diabetes mellitus
(T2DM) patients inadequately controlled on sulfonylurea (SU) ± metformin.
Methods: In this randomized, double-blind, two-arm, parallel-group, multicenter study, patients received
lixisenatide 20 μg once-daily or placebo for 24 weeks in a stepwise dose increase on top of SUs ± metformin.
Primary outcome was change in HbA1c from baseline to Week 24.
Results: Lixisenatide provided a signiﬁcant reduction in HbA1c at Week 24 versus placebo (LS mean:−0.85%
vs.−0.10%; p b 0.0001) and more patients achieved HbA1c b7.0% (36.4% vs. 13.5%; p b 0.0001). Lixisenatide
signiﬁcantly lowered FPG and body weight versus placebo. In breakfast meal test patients, lixisenatide
reduced 2-hour PPG versus placebo (LS mean: −111.48 vs. −3.80 mg/dL [−6.19 vs. −0.21 mmol/L];
p b0.0001) and glucose excursion (−94.11 vs.+6.24 mg/dL [−5.22 vs.+0.35 mmol/L]), and reduced 2-hour
glucagon, insulin, proinsulin, and C-peptide. The percentage of AEs was 68.3% for lixisenatide and 61.1% for
placebo; and for SAEs: 3.5% versus 5.6%, respectively. Lixisenatide did not signiﬁcantly increase symptomatic
hypoglycemia versus placebo (15.3% vs. 12.3%, respectively); one severe episode of hypoglycemia was
reported with lixisenatide.
Conclusions: Once-daily lixisenatide signiﬁcantly improved glycemic control, with a pronounced
postprandial effect, without signiﬁcant increase in symptomatic/severe hypoglycemia risk and with
weight loss over 24 weeks.
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Metformin remains the most widely used ﬁrst-line treatment for
Type 2 diabetes mellitus (T2DM), although treatment to maintain
glycemic control typically progresses to the use of multiple oral
antidiabetic drugs (OADs) and/or insulin (Inzucchi, Bergenstal, &
Buse, 2012). In this instance, combining a sulfonylurea (SU) with
metformin is a common treatment strategy that is drivenmainly by its
low cost (Inzucchi et al., 2012). However, as a class of drugs, SUs are
often associated with weight gain and hypoglycemia − factors that
need to be considered when subsequent add-on therapies are
required (IDF, 2005; Rodbard, Jellinger, & Davidson, 2009). The
development of glucagon-like peptide-1 (GLP-1) receptor agonists
represents an attractive strategy to improve metabolic control in
patients with T2DM; these agents achieve a physiological blood
glucose–insulin response with a low risk of hypoglycemia as a result
of their glucose-dependent action (Nauck, Heimesaat, & Behle, 2002)
and are associated with beneﬁcial effects on weight and appetite
reduction (Drucker, 2006), making them good candidates for
combination with OADs, including SUs.
Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the
treatment of T2DM. It is a 44-amino-acid peptide that is amidated at
the C-terminal amino acid and shares structural elements with
exendin-4, the primary difference being the addition of six lysine
residues at the C terminus (Werner, Haschke, & Herling, 2010). In a
13-week, randomized, double-blind, placebo-controlled, dose-rang-
ing study, lixisenatide 20 μg once-daily signiﬁcantly improved
glycated hemoglobin (HbA1c) compared with placebo in patients
with T2DM inadequately controlled with metformin, and this dose
provided the best efﬁcacy–tolerability ratio compared with 5, 10, and
30 μg once-daily and 5, 10, 20, and 30 μg twice-daily (Ratner et al.,
2010). Lixisenatide 20 μg once-daily has subsequently been shown to
signiﬁcantly improve glycemic control, with low rates of hypoglyce-
mia and beneﬁcial effects on weight, when administered as mono-
therapy (Fonseca et al., 2012), as add-on therapy to OADs (Ahrén
et al., 2013; Bolli et al., 2013; Pinget et al., 2013; Rosenstock et al.,
2013), and in combination with basal insulin with or without oral
antidiabetic therapy (Riddle et al., 2013a; Riddle et al., 2013b; Seino
et al., 2012).
In the present study, we report the 24-week results from a Phase
III, placebo-controlled study (GetGoal-S; NCT00713830) that investi-
gated the efﬁcacy and safety of lixisenatide once-daily as add-on
therapy in patientswith T2DM inadequately controlled on SU therapy,
with or without concomitant metformin. Of note is that this study
included a large subgroup of patients who underwent a meal
challenge test, allowing the rigorous assessment of postprandial
metabolic parameters.2. Methods
2.1. Study design
This was a Phase III, randomized, double-blind, placebo-controlled,
two-arm, parallel-group, multicenter, multinational study consisting
of up to 2 weeks screening and a 1-week single-blind run-in period,
followed by a 24-week main treatment period plus a controlled
extension period of variable duration of at least 52 weeks mainly for
safety purposes (not reported here). The study was conducted in 136
centers in 16 countries (Bulgaria, Czech Republic, Egypt, Germany,
India, Israel, Japan, Korea, The Netherlands, Romania, Russia, Taiwan,
Thailand, Tunisia, Turkey, and the United States). The study was
approved by the local institutional review boards or ethics commit-
tees and was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines. All patients provided
written informed consent to participate in the study.2.2. Participants
Male and female participants aged 20–79 years with T2DM
currently receiving a SU with or without metformin and with an
HbA1c level of 7–10%, inclusive, were included in the present study.
The main exclusion criteria were: Use of oral or injectable glucose-
lowering agents other than a SU or metformin within 3 months prior
to the time of screening; fasting plasma glucose (FPG) at screening
N250.0 mg/dL (N13.9 mmol/L); history of unexplained pancreatitis,
chronic pancreatitis, pancreatectomy, stomach/gastric surgery, or
inﬂammatory bowel disease; history of gastrointestinal disease with
prolonged nausea and vomiting in the 6 months prior to study
initiation; history of metabolic acidosis, including diabetic ketoaci-
dosis, within 1 year prior to screening; history of myocardial
infarction, stroke, or heart failure requiring hospitalization within
the previous 6 months; uncontrolled/inadequately controlled hyper-
tension at the time of screening, with a resting systolic blood pressure
of N180 mmHg or diastolic blood pressure N95 mmHg; amylase and/or
lipase N3 times or aspartate aminotransferase, alanine aminotrans-
ferase, or alkaline phosphatase N2 times the upper limit of the
normal laboratory range; and end-stage renal disease (deﬁned by
serum creatinine clearance of b15 mL/min) and/or dialysis. In the
case of treatment with metformin, patients with renal impairment
(deﬁned by creatinine of N1.4 mg/dL in women and N1.5 mg/dL in
men) were excluded.
2.3. Rescue policy
Routine fasting self-monitored plasma glucose (SMPG) and central
laboratory alerts on FPG (and HbA1c after Week 12) were set up to
ensure that glycemic parameters remained under predeﬁned thresh-
old values. If one fasting SMPG value exceeded the speciﬁc glycemic
limit on one day, the patient was instructed to check it again on the
following two days. If all the values in the three consecutive days
exceeded the speciﬁc limit, the patient was instructed to contact
the investigator and a central laboratory FPG measurement (and
HbA1c after Week 12) was performed. Patients were censored for
modiﬁed intent-to-treat (mITT) at the time that rescue medication
was initiated.
2.4. Randomization
Eligible patients were randomized in a 2:1 ratio to receive either
lixisenatide once-daily or matching placebo in a 2-step dose-increase
regimen (10 μg once-daily for 1 week, 15 μg once-daily for 1 week,
then 20 μg once-daily). Randomization was stratiﬁed by HbA1c at
screening (b8%, ≥8%) and metformin use at screening (yes/no).
Lixisenatide and placebo were administered subcutaneously within 1
hour before the morning meal.
During the dose-increase period, and depending on how well the
patient tolerated the titration, the investigator could maintain the
achieved dose level for an additional week before attempting a dose
increase, reduce the dose (back to 15 μg once-daily and then, if
necessary, to 10 μg once-daily), or discontinue treatment. If the dose
was not increased as initially planned, another attempt had to be
made within the subsequent 4 weeks. If the patient could not reach or
tolerate the target dose of 20 μg once-daily, the 15 μg or 10 μg daily
dose was maintained. Patients continued on their established doses of
SU and, when appropriate, of metformin. Only in the case of a
screening that resulted in HbA1c b8% was the SU dose decreased by
25–50% at the randomization visit to prevent hypoglycemia. The SU
dose was then gradually increased to the dose received at screening
between Weeks 4 and 12, according to fasting SMPG measurements.
Both treatment groups received lifestyle and dietary counseling at
screening and then every 3 months thereafter.
n=554 n=274
Fig. 1. Mean change in HbA1c from baseline to Week 24 by visit. Week 24 LOCF data
represent the LS mean change. HbA1c = glycated hemoglobin; LOCF = last observa-
tion carried forward; SE = standard error.
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The primary efﬁcacy endpoint was the absolute change in HbA1c
from baseline to Week 24 for the mITT population, which consisted of
all randomized patients who received at least one dose of double-
blind investigational product and had both a baseline and at least one
post-baseline assessment of any primary or secondary efﬁcacy
parameter. Measurement of HbA1c was performed at a National
Glycohemoglobin Standardization Program Level 1 certiﬁed central
laboratory, using a high-performance liquid chromatographymethod.
The secondary efﬁcacy measures included the percentage of patients
reaching HbA1c b7.0% or ≤6.5% at Week 24, changes in FPG and body
weight from baseline to Week 24, and the percentage of patients
requiring rescue medication during the 24-week treatment period. In
addition, in all sites in selected countries (Israel, Japan, Republic of
Korea, Russia, and the United States), all randomized patients were
selected to undergo a standardized 600 kcal liquid breakfast meal
challenge test (400 mL of Ensure Plus®, Abbott Nutrition, Columbus,
OH, USA; composed of 53.8% carbohydrate, 16.7% protein, and 29.5%
fat) 30 minutes after drug administration at baseline andWeek 24 for
assessment of the secondary efﬁcacy measure of 2-hour postprandial
plasma glucose (PPG). The 2-hour glucose excursion (an exploratory
endpoint) was calculated as 2-hour PPG minus plasma glucose levels
30 minutes prior to the meal test before study drug administration.
Changes in glucagon, plasma insulin, proinsulin, proinsulin-to-insulin
ratio, and C-peptide under fasting conditions and 2 hours after the
standardized breakfast from baseline to Week 24 were also assessed.
The safety population comprised all randomized patients exposed
to at least one dose of double-blind investigational product. Safety and
tolerability were assessed by review of adverse events (AEs),
occurrence of symptomatic and severe hypoglycemia, and clinical
laboratory data. Possible allergic reaction events were blindly
reviewed and adjudicated by the Allergic Reaction Assessment
Committee (ARAC). Symptomatic hypoglycemia was deﬁned as
symptoms consistent with hypoglycemia, with accompanying blood
glucose b60 mg/dL (3.3 mmol/L) or, if no plasma glucose measure-
ment was available, a prompt recovery with carbohydrate, intrave-
nous glucose, or glucagon administration. Severe symptomatic
hypoglycemia was deﬁned as symptomatic hypoglycemia requiring
the assistance of another person, because the patient could not treat
him/herself due to acute neurological impairment, and which was
associated eitherwith a plasma glucose level b36 mg/dL (2.0 mmol/L)
or, if no plasma glucose measurement was available, a prompt
recovery with carbohydrate, intravenous glucose, or glucagon
administration. Laboratory tests were performed for hematology,
creatinine, microalbuminuria, pregnancy (in females of childbearing
potential), and serum chemistry, including lipoproteins, amylase and
lipase, and calcitonin.
2.6. Statistical analyses
The primary efﬁcacy endpoint was analyzed using an analysis of
covariance (ANCOVA) model, with treatment group, randomization
strata and country as ﬁxed factors, and baseline HbA1c as a covariate.
Continuous secondary efﬁcacy variables were also analyzed by
ANCOVA; categorical secondary efﬁcacy variables were analyzed
using a Cochran–Mantel–Haenszel method stratiﬁed on randomiza-
tion strata. Differences between lixisenatide and placebo and two-
sided 95% conﬁdence intervals (CIs), as well as p-values, were
estimated within the framework of ANCOVA.
A sample size of 855 participants (570 in the lixisenatide group
and 285 in the placebo group) was calculated as sufﬁcient to detect a
difference of 0.4% in the absolute change from baseline in HbA1c to
Week 24 between lixisenatide and placebo, with a power of 98%. This
assumed a common standard deviation (SD) of 1.3% with a 2-sided
test at a 5% signiﬁcance level. The last observation carried forward(LOCF) procedure was used to handle missing assessments or early
discontinuation during the double-blind treatment period.
3. Results
3.1. Demographic and baseline characteristics
A total of 1438 patients were screened and 859 eligible patients
were randomized to receive either lixisenatide once-daily (n = 573)
or matching placebo (n = 286). Patient disposition is shown in
Supplementary Fig. 1. The most common reason for screening failure
was an HbA1c value out of the deﬁned protocol range at the screening
visit. All randomized patients were exposed to the study treatment
and included in the safety population. At selected sites, all randomized
patients (n = 468 [54% of the total population]; 313 lixisenatide, 155
placebo) underwent the standardized breakfast meal challenge test
and 467 (155 in the placebo group and 312 in the lixisenatide group)
were included in the mITT population.
Approximately 84% of patients were receiving metformin in
addition to their SU therapy at baseline; the remaining patients
were on SU monotherapy. The majority of patients (87% lixisenatide,
89% placebo) completed the 24-week main treatment period
(Supplementary Fig. 1). The rate of treatment discontinuation was
12.9% (n = 74) in the lixisenatide group and 10.8% (n = 31) in the
placebo group. The rate of discontinuation due to AEs was 8.4% (n =
48) with lixisenatide and 3.8% (n = 11) with placebo. Approximately
89% of patients reached and stayed on the lixisenatide maintenance
dose of 20 μg once-daily at Week 24.
Demographic and baseline characteristics were well matched
between the two study groups (Table 1). Overall, 52.2% (n = 448) of
patients were Caucasian and 44.8% (n = 385)were Asian. At baseline,
44.5% (n = 382) of patients were obese, with a mean body mass
index (BMI) of 30.2 kg/m2. Themean duration of known diabetes was
approximately 9.4 years.
3.2. Efﬁcacy
3.2.1. HbA1c
Lixisenatide resulted in a signiﬁcant reduction in HbA1c atWeek 24
versus placebo (Fig. 1). Mean (± SD) HbA1c decreased from 8.3% (0.9)
to 7.4% (1.0) with lixisenatide and from 8.2% (0.8) to 8.1% (1.1) with
placebo. The least squares (LS) mean (standard error [SE]) HbA1c
reduction at Week 24 (LOCF) was −0.85% (0.06) for lixisenatide
versus −0.10% (0.07) for placebo (LS mean difference vs. placebo:
−0.74%; 95% CI [−0.867,−0.621]; p b 0.0001). The HbA1c targets
of b7.0%and≤6.5%werebothachievedby signiﬁcantlymorepatients in
Table 1
Demographic and baseline characteristics (safety population).
Variable Lixisenatide
(n = 574)⁎
Placebo
(n = 285)⁎
Male, n (%) 284 (49.5) 150 (52.6)
Race, n (%)
Caucasian 297 (51.7) 151 (53.0)
Black 17 (3.0) 9 (3.2)
Asian 260 (45.3) 125 (43.9)
Mean age, years (SD) 57.0 (9.8) 57.8 (10.1)
Duration of diabetes, years (SD) 9.1 (6.0) 9.8 (6.2)
Weight, kg (SD) 82.6 (21.9) 84.5 (22.8)
BMI, kg/m2 (SD) 30.1 (6.6) 30.4 (6.6)
HbA1c, % (SD) 8.3 (0.9) 8.2 (0.8)
FPG, mg/dL (SD) 174.2 (39.6) 167.4 (43.2)
FPG, mmol/L (SD) 9.67 (2.2) 9.29 (2.4)
2-hour PPG, mg/dL (SD)† 299.3 (73.9) 298.2 (66.7)
2-hour PPG, mmol/L (SD)† 16.6 (4.1) 16.6 (3.7)
2-hour glucose excursion, mg/dL (SD)† 124.9 (72.1) 126.8 (59.5)
2-hour glucose excursion, mmol/L (SD)† 6.9 (3.8) 7.0 (4.0)
SU therapy (Glim/Glyb/Glic/Glip/Other), % 41/33/18/8/b1 45/32/13/9/b1
Duration of SU treatment, years (SD) 5.2 (4.4) 5.3 (4.2)
Metformin use (yes/no), % 85/15 84/16
BMI = body mass index; FPG = fasting plasma glucose; Glyb = glyburide (any
formulation); Glic = gliclazide (any formulation); Glim = glimepiride; Glip =
glipizide (any formulation); HbA1c = glycated hemoglobin; PPG = postprandial
plasma glucose; SD = standard deviation; SU = sulfonylurea.
⁎ One patient who was randomized to placebo received lixisenatide during the study
(543 out of 561 days) due to a site dispensing error and was, therefore, considered a
placebo patient in the modiﬁed intent-to-treat population (for efﬁcacy analysis), but a
lixisenatide-treated patient in the safety population (for safety analysis).
† Based on 463 patients undergoing a standardized breakfast meal challenge test at
selected sites.
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13.5% of patients, respectively, for the target of b7.0%; 19.3% and 4.7%,
respectively, for the target of ≤6.5% (p b 0.0001 for both).
3.2.2. Fasting plasma glucose
Lixisenatide provided a signiﬁcant reduction in FPG from baseline
to Week 24 compared with placebo (Fig. 2A). Mean (±SD) FPG
decreased from 174.2 (40.3) to 157.5 (41.8) mg/dL (9.7 [2.2] to 8.7
[2.3] mmol/L) with lixisenatide and from 167.4 (42.7) to 165.6 (42.0)
mg/dL (9.3 [2.4] to 9.2 [2.3] mmol/L) with placebo (LSmean difference
vs. placebo:−11.4 mg/dL, 95% CI [−16.6,−6.2];−0.6 mmol/L, 95% CI
[−0.9,−0.3]; p b 0.0001).
3.2.3. Body weight
Lixisenatide provided a signiﬁcantly greater reduction in body
weight compared with placebo (Supplementary Fig. 2). Mean (± SD)
body weight decreased from 82.6 (21.9) kg to 80.9 (21.4) kg with
lixisenatide and from 84.5 (22.8) kg to 83.6 (23.0) kg with placebo. The
LS mean (SE) body weight reduction at Week 24 (LOCF) was−1.76 ±
0.20 kg for lixisenatide versus −0.93 ± 0.23 kg for placebo (LS mean
change difference: − 0.84 kg, 95% CI [− 1.250, − 0.421];
p b 0.0001). Overall, 14.4% of lixisenatide-treated patients and
7.2% of placebo-treated patients had≥5% weight loss from baseline
to Week 24 (LOCF).
3.2.4. Rescue medication
A signiﬁcantly lower percentage of patients in the lixisenatide
group (n = 23 [4.0%]) versus the placebo group (n = 36 [12.6%])
required rescue therapy during the 24-week main treatment period
(p b 0.0001).
3.3. Meal test analysis
In the subset of patients undergoing the standardized breakfast
meal test, lixisenatide provided a signiﬁcant reduction in 2-hour
PPG from baseline to Week 24 compared with placebo (Table 2).Mean (± SD) 2-hour PPG decreased from 299.3 (73.6) to 191.2
(85.2) mg/dL (16.6 [4.1] to 10.6 [4.7] mmol/L) with lixisenatide, but
increased marginally from 298.2 (67.5) to 300.3 (70.2) mg/dL (16.6
[3.7] to 16.7 [3.9] mmol/L) with placebo (LS mean difference vs.
placebo: −107.7 mg/dL, 95% CI [−124.5, −90.8]; −6.0 mmol/L,
95% CI [−6.9, −5.0]; p b 0.0001) (Fig. 2B).
When looking speciﬁcally at the 2-hour glucose excursion, mean
(±SD) values decreased from 124.8 (68.3) to 34.9 (75.4) mg/dL (6.9
[3.8] to 1.9 [4.2] mmol/L) with lixisenatide and increased slightly
from 126.9 (72.2) to 137.2 (59.4) mg/dL (7.0 [4.0] to 7.6 [3.3] mmol/L)
with placebo (LS difference vs. placebo: −100.4 mg/dL, 95% CI
[−115.2, −85.5]; −5.6 mmol/L, 95% CI [−6.4, −4.7]) (Fig. 2B).
The 2-hour post-meal glucagon, insulin, proinsulin, and C-peptide
levels were signiﬁcantly reduced with lixisenatide relative to placebo
(Table 2). In patients treated with lixisenatide, decreases from
baseline to Week 24 in fasting levels of glucagon, insulin, proinsulin,
and C-peptide levels were also observed.3.4. Safety and tolerability
During the 24-week treatment period, the percentage of patients
with AEs was 68.3% (n = 392) in the lixisenatide group and 61.1%
(n = 174) in the placebo group. The percentage of patients with
serious AEs was 3.5% (n = 20) and 5.6% (n = 16), respectively
(Table 3). The most common AEs in the lixisenatide group were
gastrointestinal in nature, mostly nausea (Table 3). Events of nausea
in the lixisenatide treatment groupmainly occurred in the ﬁrst month
of treatment; few patients experienced nausea after Week 5.
Similarly, the frequency of vomiting events was reduced after Week
4 compared with the ﬁrst month of treatment. A higher percentage of
patients in the lixisenatide group discontinued treatment due to an AE
compared with the placebo group (Table 3). The most frequently
reported AE leading to treatment discontinuation in the lixisenatide
group was nausea (22 patients [3.8%] vs. no patients in the placebo
group). One death was reported during the 24-week treatment period
(a case of sudden cardiac death after 17 days of exposure to
lixisenatide), but it was considered not related to study treatment.
During the 24-week treatment period, injection-site reactions
were reported in 4.5% (n = 26) lixisenatide-treated and 1.8% (n = 5)
placebo-treated patients. Three patients discontinued treatment due
to an injection-site reaction, two of which were reported as being of
moderate intensity. A total of six patients (1.0%) in the lixisenatide
group reported an event adjudicated as an allergic reaction by the
ARAC. However, only one of them (0.2%) was considered possibly
related to study drug (an unspeciﬁed increasingly large local
reaction). Other events (angioedema, generalized pruritus, urticaria,
and two events of allergic rhinitis) were all considered by the ARAC
not to be related to the study drug.
The percentage of patients with symptomatic hypoglycemia was
not signiﬁcantly greater in the lixisenatide group compared with the
placebo group (15.3% [n = 88.0] vs. 12.3% [n = 35.0], respectively;
NS; Table 3). Among patients reporting at least one hypoglycemic
episode, the average number of hypoglycemic episodes per patient
was similar in the lixisenatide and placebo groups. Only one patient
(in the lixisenatide group) experienced a severe hypoglycemic event.
A slight decrease in blood pressure (both systolic and diastolic
blood pressure) from baseline to Week 24 was observed in both
treatment groups. There were minimal changes in heart rate from
baseline to Week 24 in both treatment groups (mean changes [±SD]:
−0.1 [8.7] bpm in the lixisenatide group and 0.1 [9.2] bpm in the
placebo group). There was no relevant change in lipid levels in the
lixisenatide group compared with the placebo group.
There were two patients (0.7%) with increased blood calcitonin
(calcitonin levels ≥20 ng/L) in the placebo group and four patients
(0.7%) with increased blood calcitonin in the lixisenatide group.
Fig. 2. A. Mean changes from baseline in fasting plasma glucose (mmol/L) by visit. Week 24 LOCF data represent the LS mean change. FPG = fasting plasma glucose; LS = least
squares, LOCF = last observation carried forward; SE = standard error. B. 2-hour postprandial plasma glucose (i) and glucose excursion (ii) changes from baseline to Week 24
(LOCF) (mmol/L). LOCF = last observation carried forward; LS = least squares, PPG = postprandial plasma glucose.
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In this placebo-controlled trial, the GLP-1 receptor agonist
lixisenatide administered at a dose of 20 μg once-daily provided a
signiﬁcant improvement in glycemic control in patients inadequately
controlled on SU therapy, including 84% of those receiving both SU and
metformin. Lixisenatide signiﬁcantly reducedHbA1c atWeek24 versus
placebo (−0.85% vs.−0.10%) and allowed considerablymore patients
to achieve the HbA1c targets of b7.0% and ≤6.5%. Maximum HbA1c
reductionwas observed atWeek 12 and the effect was sustained up tothe study end (Fig. 1). In addition, there were signiﬁcant reductions in
FPG and body weight compared with placebo. Notably, these
improvements in glycemic control with lixisenatide were mainly at
the expense of robust postprandial reductions during a meal test and
occurred without imparting any signiﬁcant increase in the proportion
of patients experiencing symptomatic hypoglycemia versus placebo
(15.3% vs. 12.3%, respectively).
The magnitude of the HbA1c reduction reported here in patients
receiving lixisenatide and SU therapy (and metformin for the
majority) is similar to that reported with exenatide 10 μg twice-
Table 2
24-week changes in 2-hour postprandial parameters in the subset of patients undergoing the standardized breakfast meal test (mITT population).
Parameter Lixisenatide Placebo LS mean difference [95% CI]
2-hour postprandial plasma glucose (mmol/L) [mg/dL] N 249 120
Baseline (SD) 16.6 (4.1)
[299.3 (73.6)]
16.6 (3.7)
[298.2 (67.5)]
Week 24 (SD) 10.6 (4.7)
[191.2 (85.2)]
16.7 (3.9)
[300.3 (70.2)]
LS mean change ± SE −6.2 (0.4)
[−111.5 (7.3)]
−0.2 (0.5)
[−3.8 (8.8)]
−5.98 [−6.91, −5.04]⁎
Glucose excursion (mmol/L) [mg/dL] N 249 120
Baseline (SD) 6.9 (3.8)
[124.8 (68.3)]
7.0 (4.0)
[126.8 (72.2)]
Week 24 (SD) 1.9 (4.2)
[34.9 (75.4)]
7.6 (3.3)
[137.2 (59.4)]
LS mean change (SE) −5.2 (0.4)
[−93.7 (7.2)]
+0.4 (0.4)
[7.2 (7.2)]
−5.57 [−6.40, −4.74]
Glucagon (ng/L) N 234 114
Baseline (SD) 97.4 (31.7) 100.3 (39.0)
Week 24 (SD) 77.6 (30.1) 100.0 (38.8)
LS mean change (SE) −23.3 (2.5) −1.2 (3.0) −22.14 [−27.91,−16.37]
Insulin (pmol/L) N 244 120
Baseline (SD) 256.6 (176.8) 279.8 (241.1)
Week 24 (SD) 195.1 (180.9) 270.2 (232.9)
LS mean change (SE) −67.7 (15.9) −2.22 (18.8) −65.5 [−100.2, −30.7]
Proinsulin (pmol/L) N 193 93
Baseline (SD) 62.1 (44.6) 60.1 (45.9)
Week 24 (SD) 55.2 (49.3) 61.0 (44.3)
LS mean change (SE) −4.2 (3.6) +3.6 (4.2) −7.75 [−15.13, −0.37]
C-peptide (nmol/L) N 248 119
Baseline (SD) 2.0 (0.9) 2.1 (1.0)
Week 24 (SD) 1.7 (0.9) 1.9 (1.0)
LS mean change (SE) −0.4 (0.1) −0.1 (0.1) −0.23 [−0.40,–0.07]
Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the meal test before study drug administration.
CI = conﬁdence interval; LS = least squares; mITT = modiﬁed intent-to-treat; PPG = postprandial plasma glucose; SD = standard deviation; SE = standard error.
⁎ p b 0.0001 (p values not available for other measures, as they were exploratory endpoints).
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8.5% to 7.7%]), but this occurred alongside a 2.2-fold increase in the
incidence of overall hypoglycemia with exenatide (27.8% vs. 12.6% of
patients on placebo; no severe cases) (Kendall, Riddle, & Rosenstock,
2005). Exenatide 10 μg twice-daily over 30 weeks also provided a
similar improvement in glycemia control in patients on SU mono-
therapy (−0.9% [from 8.6% to 7.7%]), but markedly increased the
incidence of overall hypoglycemia by 11-fold (35.7% vs. 3.3% on
placebo; no severe cases) (Buse, Henry, & Han, 2004).
In the LEAD-1 study involving patients on glimepiride mono-
therapy, add-on liraglutide 1.2 mg and 1.8 mg once-daily provided
reductions in HbA1c of−1.1% for both doses (Marre, Shaw, & Brandle,
2009). In absolute terms, hypoglycemia rates were lower than in
GetGoal-S, possibly due to a lower threshold in deﬁning events (minor
episodes [FPG b3.1 mmol/L]: 9.1% [1.2 mg], and 8.2% [1.8 mg]; oneTable 3
Adverse events (AEs) during the 24-week, double-blind treatment period – safety populati
Type of adverse event Lixis
Any AE, n (%) 392
Any serious AE, n (%) 20
Death, n (%) 1
Discontinuation due to AE, n (%) 56
Gastrointestinal disorders (any), n (%) 235
Nausea, n (%) 145
Vomiting, n (%) 50
Diarrhea, n (%) 51
Symptomatic hypoglycemia†, n (%) 88
Severe hypoglycemia‡, n (%) 1
AE = adverse event.
⁎ Sudden cardiac death after 17 days of exposure.
† Symptomatic hypoglycemia = episode with clinical symptoms with either plasma gluco
(if no plasma glucose measurement was available).
‡ Severe hypoglycemia = symptomatic hypoglycemia in which the patient required the as
b36 mg/dL (2.0 mmol/L) or, if no plasma glucose measurement was available, prompt recomajor episode with 1.8 mg). However, this represented a greater than
3-fold increase relative to placebo (2.6%) in LEAD-1 compared to a
marginal difference versus placebo in our study (Marre et al., 2009).
As mentioned above, the most notable result from the present
study was the pronounced postprandial effect observed with
lixisenatide during the breakfast meal challenge, with signiﬁcant
placebo-subtracted reductions (N100 mg/L [N5.56 mmol/L]) for both
2-hour PPG and glucose excursion. This represents an approximately
80% reduction in 2-hour glucose excursion compared with placebo.
This result is from 369 patients analyzed (including 249 patients on
lixisenatide) and represents one of the most comprehensive meal
challenge assessments for any GLP-1 receptor agonist. In the present
study, lixisenatide also reduced postprandial glucagon, insulin, and
proinsulin levels during the meal test. This comprehensive postpran-
dial effect observed with lixisenatide is associated with its effect onon.
enatide (n = 574) Placebo (n = 285)
(68.3) 174 (61.1)
(3.5) 16 (5.6)
(0.2)⁎ 0
(9.8) 14 (4.9)
(40.9) 57 (20.0)
(25.3) 20 (7.0)
(8.7) 10 (3.5)
(8.9) 19 (6.7)
(15.3) 35 (12.3)
(0.2) 0
se b60 mg/dL (3.3 mmol/L) or prompt recovery after oral carbohydrate administration
sistance of another person, and which was associated either with a plasma glucose level
very with carbohydrate.
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double-blind, placebo-controlled, parallel-group study reported that
lixisenatide 20 μg once-daily reduced postprandial glycemic excur-
sions in patients with T2DM, together with a sustained slowing of
gastric emptying (Lorenz et al., 2013).
Moreover, results from a 4-week, randomized, open-label, repeat-
ed-dose study in patients with T2DM inadequately controlled on
metformin demonstrated that lixisenatide 20 μg once-daily has a
signiﬁcantly greater PPG-lowering effect than liraglutide 1.8 mg once-
daily. Overall, lixisenatide provided a signiﬁcantly greater reduction in
PPG (glucose AUC0:30–4:30h) compared with liraglutide (p b 0.0001).
Furthermore, lixisenatide provided signiﬁcantly greater reductions in
maximum PPG excursion compared with liraglutide (−70.5 mg/dL
[−3.91 mmol/L] with lixisenatide vs. −24.9 mg/dL [−1.38 mmol/L]
with liraglutide; p b 0.0001). A greater proportion of lixisenatide-
treated patients (69%) also achieved 2-hour PPG levels b140 mg/dL
(b7.8 mmol/L) at Day 28 compared with liraglutide-treated patients
(29%) (Kapitza, Forst, & Coester, 2013). This is probably related to a
greater effect on slowing gastric emptying as longer-acting GLP-1
receptor agonists, such as liraglutide, have little to no effect on gastric
emptying due to tachyphylaxis (Meier, 2012).
As expected, the most frequent AEs associated with lixisenatide
were gastrointestinal. The majority of these events were mild or
moderate nausea and vomiting that were transient, occurring mostly
during the ﬁrst 4 weeks. The nausea incidence of 25% over 24 weeks is
generally comparable to studies with other GLP-1 receptor agonists,
which range widely from 13% to 51% with exenatide 10 μg twice-daily
and from5% to 29%with liraglutide 1.2 and1.8 mgonce-daily (Aroda&
Ratner, 2011; Montanya & Sesti, 2009). Furthermore, the incidence of
nausea in this study is virtually identical to that fromanother 24-week,
randomized trial in which fewer patients reported nausea with
lixisenatide 20 μg once-daily compared with exenatide 10 μg twice-
daily (24.5% vs. 35.1%, respectively; p b 0.05) (Rosenstock et al., 2013).
It should be noted that 84% of the patients were inadequately
controlled on the combination of a SUwithmetformin at study end. As
such, this represented a population with relatively advanced disease.
Such patients would typically be candidates for basal insulin therapy
as the next step in their treatment intensiﬁcation (IDF, 2005; Nathan
et al., 2009; Rodbard et al., 2009). The postprandial characteristic
makes lixisenatide an attractive option for use in combination with
agents that mainly target FPG, including SU or basal insulin.
In conclusion, in patients with T2DM uncontrolled on a SU with or
without metformin, add-on treatment with lixisenatide 20 μg once-
daily provided signiﬁcant improvements in glycemic control –
including a pronounced postprandial effect – with weight loss and
without increasing symptomatic or severe hypoglycemia risk over 24
weeks. Reduction of the dose of the SU may be considered to further
reduce the risk of hypoglycemia. Beneﬁcial effects on weight and no
increased risk of hypoglycemia in spite of improved glycemic control
are particularly desirable characteristics for an add-on therapy in
patients receiving a SU. The results demonstrated the efﬁcacy–
tolerability proﬁle of lixisenatide once-daily in the context of SU-
based oral agent failure and highlighted its potential as a valuable
option for the treatment of T2DM.
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